Evidence map›Paper›PMID 36424645›Full record

ArticleJournal of nanobiotechnology2022

A carbon monoxide releasing metal organic framework nanoplatform for synergistic treatment of triple-negative breast tumors.

Yiyang Cong, Bo Sun, Jianlun Hu, Xiaoyang Li, Yanan Wang, Jingyi Zhang, Dongzhi Yang, Weifei Lu, Zhi Ding, Xiaofeng Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 14 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yiyang CongState Key Laboratory of Pharmaceutical Biotechnology School of Life Sciences, Nanjing University, 163 Xianlin Avenue, Nanjing, 210093, China.
Bo SunJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Jianlun HuState Key Laboratory of Pharmaceutical Biotechnology School of Life Sciences, Nanjing University, 163 Xianlin Avenue, Nanjing, 210093, China.
Xiaoyang LiState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, 210093, China.
Yanan WangCollege of Veterinary Medicine, Henan Agriculture University, Zhengzhou, 450002, Henan, China.
Jingyi ZhangCollege of Veterinary Medicine, Henan Agriculture University, Zhengzhou, 450002, Henan, China.
Dongzhi YangJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China. dongzhiy@xzhmu.edu.cn.
Weifei LuCollege of Veterinary Medicine, Henan Agriculture University, Zhengzhou, 450002, Henan, China.
Zhi DingState Key Laboratory of Pharmaceutical Biotechnology School of Life Sciences, Nanjing University, 163 Xianlin Avenue, Nanjing, 210093, China. dingzhi@nju.edu.cn.
Xiaofeng WangNanjing Key Laboratory of Advanced Functional Materials, Nanjing Xiaozhuang University, Nanjing, 211171, People's Republic of China.
Hao HongState Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, 210093, China. haohong@nju.edu.cn.
Nanjing University · CNHenan Agricultural University · CNXuzhou Medical College · CNNanjing Xiaozhuang University · CNState Key Laboratory of Pharmaceutical Biotechnology

Funding

Jiangsu Graduate Scientific Research Innovation Project KYCX22_2963Technical Innovation Fund of Nanjing University 14913416The Research Team Start-up Funds of Nanjing University 14912204Thousand Young Talents Program of China 13004002
6 · The paper itself

Abstract

backgroundCarbon monoxide (CO) is an important signaling molecule participating in multiple biological functions. Previous studies have confirmed the valuable roles of CO in cancer therapies. If the CO concentration and distribution can be controlled in tumors, new cancer therapeutic strategy may be developed to benefit the patient survival.

resultsIn this study, a UiO-67 type metal-organic framework (MOF) nanoplatform was produced with cobalt and ruthenium ions incorporated into its structure (Co/Ru-UiO-67). Co/Ru-UiO-67 had a size range of 70-90 nm and maintained the porous structure, with cobalt and ruthenium distributed uniformly inside. Co/Ru-UiO-67 was able to catalyze carbon dioxide into CO upon light irradiation in an efficient manner with a catalysis speed of 5.6 nmol/min per 1 mg Co/Ru-UiO-67. Due to abnormal metabolic properties of tumor cells, tumor microenvironment usually contains abundant amount of CO

conclusionThis nanoscale UiO-67 MOF platform can further our understanding of CO functions while produce CO in a controllable manner during cancer therapeutic administration.

Indexed as

Metal-Organic FrameworksRutheniumTriple Negative Breast NeoplasmsCarbon DioxideCarbon MonoxideCobaltHumansTumor MicroenvironmentCarbon DioxideCarbon MonoxideCobaltMetal-Organic FrameworksRutheniumUiO-67Carbon monoxideCatalysisImagingMetal–organic frameworkSynergistic therapy

Identifiers

PMID36424645
PMCPMC9685850
OpenAlexW4309889354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.